Literature DB >> 12469784

Metastatic breast cancer to 4 eyelids: a clinicopathologic report.

Raymond S Douglas1, Scott M Goldstein, Eugene Einhorn, Michael S Ibarra, Roberta E Gausas.   

Abstract

A 47-year-old woman presented complaining of progressive, painless swelling of all 4 eyelids for 6 weeks. Her medical history was significant for breast cancer 14 months prior. Examination results showed a diffuse, firm thickening of all 4 eyelids with mild erythema of the overlying skin. Orbital computer tomography revealed extensive preseptal infiltration of soft tissue of all 4 eyelids, which enhanced with contrast. Results of a bilateral biopsy of the upper eyelids demonstrated extensive infiltration of the orbicularis muscle. Histologic features were consistent with metastatic breast cancer. Results of both the primary breast cancer biopsy taken 14 months previously and the eyelid biopsies were the same histologic type. Presentation of metastatic breast cancer to the eyelids is rare, but a recurrence must be considered in any patient with a history of breast cancer, despite the length of tumor-free survival. Bilateral involvement should not exclude metastases from diagnostic consideration, but rather, the diagnosis requires a high degree of clinical suspicion and recognition of the various cutaneous forms.

Entities:  

Mesh:

Year:  2002        PMID: 12469784

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  2 in total

Review 1.  Cutaneous metastases of visceral tumours: a review.

Authors:  Dorothée Nashan; Marcel Lucas Müller; Markus Braun-Falco; Sebastian Reichenberger; Rolf-Markus Szeimies; Leena Bruckner-Tuderman
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

Review 2.  Rare sites of breast cancer metastasis: a review.

Authors:  Rosa Di Micco; Letizia Santurro; Maria Luisa Gasparri; Veronica Zuber; Enrico Fiacco; Guglielmo Gazzetta; Chanel Elisha Smart; Alice Valentini; Oreste Davide Gentilini
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.